A key diagnostic indicator for Lambert-Eaton Myasthenic Syndrome (LEMS) in small cell lung cancer (SCLC) patients is weakness that seems disproportionately severe compared to their observable disease status. This clinical suspicion should prompt investigation beyond assuming it's a typical cancer-related symptom, especially if a characteristic shuffled gait is present.
An ongoing study is assessing routine LEMS antibody screening for all SCLC patients. However, a positive result in an asymptomatic patient could wrongly deter oncologists from using highly effective therapies like immunotherapy or T-cell engagers due to unsubstantiated fears of triggering a neurologic flare, for which there is currently no evidence.
While both are autoimmune neuromuscular disorders, their clinical presentations differ significantly at onset. Myasthenia Gravis typically starts with ocular (droopy eyelids, double vision) and bulbar (swallowing) symptoms. In contrast, LEMS begins with proximal muscle weakness (difficulty rising from a chair), with ocular symptoms appearing only in advanced stages.
Despite patients with paraneoplastic syndromes being excluded from immunotherapy trials, clinical experience suggests it can be a viable option. For patients whose LEMS is neurologically stable and not requiring escalating immunosuppression, a shared decision-making discussion can lead to the successful use of immunotherapy or T-cell engagers without necessarily causing a flare.
Amifampridine significantly improves muscle weakness and quality of life for LEMS patients. However, it should be viewed as a maintenance supportive care medication. Clinical experience shows that attempts to taper the drug off, even when patients feel well, often result in a return of muscle weakness, requiring them to stay on it long-term.
Given that access to neuromuscular specialists can be a significant bottleneck, oncologists should not delay investigating suspected LEMS. The diagnostic process can be initiated directly in the oncology clinic with a simple blood draw to test for anti-VGCC antibodies. This empowers oncologists to expedite diagnosis and subsequent management.
Not all paraneoplastic syndromes are equal in severity. Endocrine syndromes like SIADH are generally manageable and reversible with anti-cancer therapy. In contrast, neurologic syndromes like LEMS are more debilitating and persistent, causing significant disability and posing a greater challenge when considering aggressive treatments like immunotherapy.
A powerful case study showed a patient with well-controlled LEMS, who initially deferred immunotherapy, was later treated with durvalumab plus chemotherapy upon recurrence. She achieved a complete radiographic response and continued durvalumab maintenance for 10 months without worsening her LEMS, supporting the cautious use of immunotherapy in this population.
Even after a complete cancer response and LEMS-specific treatments, patients often retain a degree of underlying proximal muscle weakness that never fully resolves. This suggests the neuromuscular damage may be permanent, setting realistic long-term expectations for patient functionality and highlighting the need for ongoing supportive care like amifampridine.